PUBLISHER: The Business Research Company | PRODUCT CODE: 1662923
PUBLISHER: The Business Research Company | PRODUCT CODE: 1662923
Catalepsy treatment involves procedures aimed at alleviating symptoms such as loss of voluntary motion, fixed posture, and decreased pain sensitivity commonly associated with catalepsy. This treatment typically employs medications and muscle relaxants to reduce muscle rigidity.
The primary categories of catalepsy treatment include drugs, psychotherapy, and other therapeutic interventions. Drugs encompass various substances used to diagnose, treat, or alleviate symptoms of the condition. These medications are administered through oral, parenteral, and alternative routes, and are commonly utilized in hospitals, specialized clinics, and various other healthcare facilities catering to patients with catalepsy.
The catalepsy treatment market research report is one of a series of new reports from The Business Research Company that provides catalepsy treatment market statistics, including catalepsy treatment industry global market size, regional shares, competitors with a catalepsy treatment market share, detailed catalepsy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the catalepsy treatment industry. This catalepsy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The catalepsy treatment market size has grown strongly in recent years. It will grow from $87.07 billion in 2024 to $92.7 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to economic factors, awareness and education, healthcare infrastructure development, drug approvals and regulatory landscape, advancements in medical research.
The catalepsy treatment market size is expected to see strong growth in the next few years. It will grow to $123.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to investment and funding, global health trends, patient advocacy and awareness programs, healthcare policy changes, innovations in drug development. Major trends in the forecast period include collaborative research initiatives, neurostimulation therapies, regulatory landscape changes, patient advocacy and awareness, digital health integration.
The catalepsy treatment market is anticipated to experience growth due to the increasing prevalence of chronic diseases. Chronic conditions, characterized by lasting three months or longer and often progressing over time, impact a significant portion of the global population, particularly the elderly. Catalepsy, associated with toxic or infectious diseases linked to chronic illnesses, is on the rise, necessitating effective treatment. As of September 2022, the World Health Organization reported that approximately 41 million people, accounting for 74% of global deaths, succumb to chronic noncommunicable diseases (NCD) annually. Notably, 77% of NCD deaths occur in low- and middle-income countries. This escalation in chronic diseases is a driving force behind the growth of the catalepsy treatment market.
The increasing prevalence of neurological disorders is poised to contribute to the expansion of the catalepsy treatment market. Neurological disorders, encompassing various medical conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves, necessitate effective catalepsy treatment to manage symptoms, slow disease progression, enhance quality of life, and prevent or manage complications. According to The European Academy of Neurology, neurological disorders impact 1 in 3 individuals at some point in their lives, emphasizing the significant and widespread nature of these conditions. This growing prevalence of neurological disorders acts as a key driver for the catalepsy treatment market.
Product innovation is a significant trend gaining traction in the catalepsy treatment market. Leading companies in this field are concentrating on developing innovative solutions to enhance their market position. For example, in March 2024, Luigi Pavia, an Italy-based ecosystem engagement company, formed a partnership with Frontiers Health, a Switzerland-based firm focused on innovative healthcare solutions, particularly in digital health and telehealth integration. Through this collaboration, they aim to promote open innovation by tackling specific processes and therapeutic challenges. Their initiatives include organizing tailored events such as pitch competitions and hackathons, even adapting to virtual formats during the pandemic to sustain engagement and effectiveness.
Major companies in the catalepsy treatment market are directing their focus towards innovative products, such as baclofen oral granules, to drive revenue growth. Baclofen oral granules represent a specific form of baclofen medication formulated in granular or powder form for oral administration. For example, in June 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, introduced lyvispah to the market. Lyvispah is designed to work on spinal cord nerves, reducing the frequency and intensity of muscular spasms in individuals with specific spinal cord-related disorders. This innovative product is a strawberry-flavored, dissolvable granular formulation of baclofen, available in packets containing 5 mg, 10 mg, and 20 mg. It is accessible through specialist and retail channels, providing patients with a convenient and palatable treatment option.
In October 2022, Pfizer Inc., a pharmaceutical company based in the United States, acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition is intended to bolster Pfizer's portfolio, while Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing shares to its shareholders. Biohaven Ltd. retains non-CGRP pipeline compounds and certain assets, with Pfizer owning about 3% of the new company's shares. Biohaven Pharmaceutical Holding Company Ltd. is a biotechnology firm located in the US that focuses on developing therapeutic solutions, including treatments for catalepsy.
Major companies operating in the catalepsy treatment market include Upsher-Smith Laboratories LLC, Piramal Enterprises Ltd., Vintage Labs Private Limited, Hikma Pharmaceuticals plc, CASI Pharmaceuticals Inc., Covis Pharma GmbH, GSK plc, Bayer AG, Novartis AG, Aleva Neurotherapeutics SA, Sanofi S.A., Takeda Pharmaceutical Company Limited, Roche Holding AG, Abbott Laboratories, Pfizer Inc., Johnson & Johnson Services Inc., Dr. Reddy's Laboratories Ltd., Mylan N.V., Eisai Co. Ltd., Glenmark Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Biogen Inc., Amgen Inc., AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk A/S, Boehringer Ingelheim International GmbH
North America was the largest region in the catalepsy treatment market in 2024. The regions covered in the catalepsy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the catalepsy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The catalepsy treatment market consists of sales of benzodiazepines and zolpidem. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Catalepsy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on catalepsy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for catalepsy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The catalepsy treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.